[go: up one dir, main page]

WO1993013797A3 - Vaccin conjugue a base de toxine du cholera et de lypopolysaccharide (lps) detoxique, utilise pour la prevention du cholera - Google Patents

Vaccin conjugue a base de toxine du cholera et de lypopolysaccharide (lps) detoxique, utilise pour la prevention du cholera Download PDF

Info

Publication number
WO1993013797A3
WO1993013797A3 PCT/US1993/000253 US9300253W WO9313797A3 WO 1993013797 A3 WO1993013797 A3 WO 1993013797A3 US 9300253 W US9300253 W US 9300253W WO 9313797 A3 WO9313797 A3 WO 9313797A3
Authority
WO
WIPO (PCT)
Prior art keywords
cholera
lps
conjugates
cholera toxin
disclosed
Prior art date
Application number
PCT/US1993/000253
Other languages
English (en)
Other versions
WO1993013797B1 (fr
WO1993013797A2 (fr
Inventor
Shousun C Szu
John B Robbins
Rajesh K Gupta
Original Assignee
Us Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Health filed Critical Us Health
Priority to AU34696/93A priority Critical patent/AU678549B2/en
Priority to JP5512624A priority patent/JPH07503238A/ja
Priority to EP93903428A priority patent/EP0623026A1/fr
Publication of WO1993013797A2 publication Critical patent/WO1993013797A2/fr
Publication of WO1993013797A3 publication Critical patent/WO1993013797A3/fr
Publication of WO1993013797B1 publication Critical patent/WO1993013797B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/107—Vibrio
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6087—Polysaccharides; Lipopolysaccharides [LPS]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention décrit une formulation de vaccin comprenant des conjugués composés de LPS détoxiqués et de protéines comprenant la toxine du choléra (CT). Le traitement à l'aide de l'hydrazine (DeA-LPS) réduit les caractéristiques endotoxiques du LPS à des niveaux admissibles, et produit une molécule plus importante, et à activité/antigénique accrue, par rapport au saccharide produit par hydrolyse acide. Des conjugués utilisant la toxine de V. cholerae sont également décrit, lesquels présentent de faibles niveaux de pyrogènes, aucune activité toxique par rapport aux cellules ovariennes du hamster chinois, et induisent des réponses de renforcement chez les anticorps vibriocides et les anticorps dirigés contre la toxine du choléra lorsqu'ils sont injectés par voie sous-cutanée sous forme de solutions salines dans des souris. Les conjuguées produits sous forme de vaccin contre le choléra induisent la formation des mêmes anticorps que les vaccins cellulaires à injection parentérale, mais présentent des caractéristiques immunologiques et une sécurité améliorées.
PCT/US1993/000253 1992-01-16 1993-01-14 Vaccin conjugue a base de toxine du cholera et de lypopolysaccharide (lps) detoxique, utilise pour la prevention du cholera WO1993013797A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU34696/93A AU678549B2 (en) 1992-01-16 1993-01-14 Detoxified LPS-cholera toxin conjugate vaccine for prevention of cholera
JP5512624A JPH07503238A (ja) 1992-01-16 1993-01-14 コレラ予防用の無毒化ｌｐｓ−コレラ毒素結合ワクチン
EP93903428A EP0623026A1 (fr) 1992-01-16 1993-01-14 Vaccin conjugue a base de toxine du cholera et de lypopolysaccharide (lps) detoxique, utilise pour la prevention du cholera

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US82145392A 1992-01-16 1992-01-16
US07/821,453 1992-01-16

Publications (3)

Publication Number Publication Date
WO1993013797A2 WO1993013797A2 (fr) 1993-07-22
WO1993013797A3 true WO1993013797A3 (fr) 1993-10-28
WO1993013797B1 WO1993013797B1 (fr) 1994-01-20

Family

ID=25233450

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1993/000253 WO1993013797A2 (fr) 1992-01-16 1993-01-14 Vaccin conjugue a base de toxine du cholera et de lypopolysaccharide (lps) detoxique, utilise pour la prevention du cholera

Country Status (5)

Country Link
EP (1) EP0623026A1 (fr)
JP (1) JPH07503238A (fr)
AU (1) AU678549B2 (fr)
CA (1) CA2128212A1 (fr)
WO (1) WO1993013797A2 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998026799A1 (fr) * 1996-12-18 1998-06-25 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Vaccin conjugue contre la salmonella paratyphi a
US6531131B1 (en) 1999-08-10 2003-03-11 The United States Of America As Represented By The Department Of Health And Human Services Conjugate vaccine for Neisseria meningitidis
JP2004515450A (ja) 2000-04-18 2004-05-27 エンドバイオロジックス， インコーポレイテッド 敗血症処置のためのリポ多糖結合体ワクチン
US7749511B2 (en) 2000-04-18 2010-07-06 Endobiologics, Incorporated Anti-sepsis conjugate vaccine
WO2002020059A2 (fr) * 2000-09-01 2002-03-14 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Vaccins conjugues a base de vibrio cholerae o139
WO2002080964A1 (fr) * 2001-04-06 2002-10-17 Institut Pasteur Vaccin conjugue d'un fragment de polysaccharide de lipopolysaccharide du vibrio cholerae 0139 lie a l'anatoxine tetanique
WO2003094961A1 (fr) 2002-05-09 2003-11-20 Massimo Porro Vaccins de polysaccharides et de glycoconjugues ameliores
WO2004043489A1 (fr) * 2002-11-14 2004-05-27 Instituto Finlay. Centro De Investigacion-Produccion De Vacunas Y Sueros. Procede d'obtention de vaccins conjugues et de compositions vaccinales qui les contiennent.
US8048432B2 (en) 2003-08-06 2011-11-01 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Polysaccharide-protein conjugate vaccines
CN102824632A (zh) * 2012-09-12 2012-12-19 北京民海生物科技有限公司 霍乱弧菌o1群多糖结合疫苗、其制备方法及应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2532850A1 (fr) * 1982-09-15 1984-03-16 Pasteur Institut Conjugues immunogenes entre un haptene et une molecule porteuse derivee d'une toxine, les vaccins les composant et procede pour leur obtention
EP0306607A1 (fr) * 1983-03-14 1989-03-15 Miles Inc. Vaccin pour des bactéries gram-négatives

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2532850A1 (fr) * 1982-09-15 1984-03-16 Pasteur Institut Conjugues immunogenes entre un haptene et une molecule porteuse derivee d'une toxine, les vaccins les composant et procede pour leur obtention
EP0306607A1 (fr) * 1983-03-14 1989-03-15 Miles Inc. Vaccin pour des bactéries gram-négatives

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
BROWN, F., R. M. CHANOCK AND R. A. LERNER (ED.). NEW APPROACHES TO IMMUNIZATION: DEVELOPING VACCINES AGAINST PARASITIC, BACTERIAL, AND VIRAL DISEASES; 1986, pages 231 - 234 KABIR, S. 'PREPARATION AND IMMUNOGENICITY OF A SEMISYNTHETIC BIVALENT CELL-SURFACE PROTEIN-POLYSACCHARIDE CONJUGATE OF VIBRIO-CHOLERAE.' *
EUR. J. BIOCHEM., VOL. 97, NO. 2, PAGE(S) 623-9, July 1979, TANAMOTO K ET AL. 'Regions of the lipopolysaccharide of Pseudomonas aeruginosa essential for antitumor and interferon-inducing activities.' *
INFECT. IMMUN., VOL. 13, NO. 3, PAGE(S) 735-740, 1976, WASHINGTON, US SVENNERHOLM A M ET AL. 'Synergistic protective effect in rabbits of immunization with vibrio cholerae lipopolysaccharide and toxin/toxoid.' *
INFECT. IMMUN., VOL. 60, NO. 8, PAGE(S) 3201-3208 1992, GUPTA R K ET AL 'Synthesis, characterization, and some immunological properties of conjugates composed of the detoxified lipopolysaccharide of Vibrio cholerae O1 serotype inaba bound to cholera toxin.' *
J. INFECT. DIS., VOL. 161, NO. , PAGE(S) 821-832, 1990, J. B. ROBBINS & R. SCHNEERSON 'Polysaccharide-protein conjugates: a new generation of vaccines.' *
MICROBIOL. ABSTR. B vol. 6, no. 1, October 1970, page 72 M. TORII ET AL. 'Immunochemical studies on O-antigens of Vibrio parahaemolyticus. 2. Effect of alkali and acid on specificity.' *
MICROBIOL. IMMUNOL., VOL. 23, NO. 2, PAGE(S) 87-94, 1979, EGAWA K ET AL. 'Endotoxic glycolipid as a potent depressor of the hepatic drug-metabolizing enzyme systems in mice.' *
PATENT ABSTRACTS OF JAPAN vol. 010, no. 287 (C-375)30 September 1986 *
SOUTHEAST ASIAN J TROP MED PUBLIC HEALTH., VOL. 18, NO. 2, PAGE(S) 142-148, 1987, CHAICUMPA W ET AL. 'ORAL VACCINE AGAINST CHOLERA PREPARED FROM VIBRIO-CHOLERAE ANTIGENS.' *
VACCINE, VOL. 9, NO. 1, PAGE(S) 53-59, January 1991, GB M. CHONGSA-NGUAN ET AL. 'IMMUNOGENECITY OF TWO FORMULATIONS OF ORAL CHOLERA VACCINES IN THAI VOLUNTEERS' *

Also Published As

Publication number Publication date
AU3469693A (en) 1993-08-03
JPH07503238A (ja) 1995-04-06
WO1993013797A2 (fr) 1993-07-22
EP0623026A1 (fr) 1994-11-09
AU678549B2 (en) 1997-06-05
CA2128212A1 (fr) 1993-07-22

Similar Documents

Publication Publication Date Title
EP0118831B1 (fr) Vaccins pour les bactéries gram-négatives et leur procédé de préparation
US20120014991A1 (en) Novel, non-antigenic, mucosal adjuvant formulation which modulates the effects of substances, including vaccine antigens, in contact with mucosal body surfaces
AU5017093A (en) Pertussis toxin used as a carrier protein with non-charged saccharides in conjugate vaccines
EP1238677A3 (fr) Emulsions grasses parentérales, comprenant de l'EDTA comme conservateur
CA2223063A1 (fr) Amelioration de l'administration de medicaments par saponines modifiees
BR9507400A (pt) Composições imunogénicas de polissacaridio streptococal grupo a e processos
WO1993013797A3 (fr) Vaccin conjugue a base de toxine du cholera et de lypopolysaccharide (lps) detoxique, utilise pour la prevention du cholera
CA2208047A1 (fr) Accroissement des concentrations de creatine et de glycogene dans les muscles
Hikino et al. Isolation and hypoglycemic activity of trichosans A, B, C, D, and E: glycans of Trichosanthes kirilowii roots1
CA2158651C (fr) Vaccins clostridiaux a plusieurs composantes, utilisant des adjuvants a base de saponine
WO1993013797B1 (fr) Vaccin conjugue a base de toxine du cholera et de lypopolysaccharide (lps) detoxique, utilise pour la prevention du cholera
CN100526876C (zh) 一种未甲基化CpG二核苷酸的含量的检测方法
Gray et al. Immunosuppressive effects of adamantoyl cytarabine—I: Inhibition of hemagglutinin formation0 and graft versus host reactions in mice
CA2255867C (fr) Immunostimulation induite par le chitosane
Kita et al. Requirement of the conformational stability of a Salmonella ribosomal vaccine for its mouse protection
Brown et al. Morphological, chemical and antigenic characterization of M-1 N-acetylmuramidase-digested cell walls of the oral pathogenic bacterium Actinomyces viscosus T14V and T14AV
KIM et al. Effects of Scopolamine Patches on Pupil and Accommodation
Martin UN: VERSITY Of UTAH LIBRARIES
Seifert et al. The effect of muramyl dipeptide on the utilization of pyrinidine precursors for DNA synthesis in rat
Riveau et al. Possibility of a direct pyrogenic effect of muramyl dipeptide
Resl et al. Development of local morphological changes after intradermal inoculation of Q-fever chemovaccine
WO1995016453A1 (fr) Medicament, conditionnement d'un medicament, et procede d'administration d'un medicament
NZ241920A (en) Vaccine preparations containing vitamin b12 (cyanocobalamin)
RU2000132456A (ru) Комбинированный препарат против сибирской язвы, анаэробной дизентерии, инфекционной энтеротоксемии и нематодозов овец и способ профилактики этих болезней

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
COP Corrected version of pamphlet

Free format text: PAGES 1/4-4/4,DRAWINGS,REPLACED BY NEW PAGES 1/5-5/5;DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

EX32 Extension under rule 32 effected after completion of technical preparation for international publication
AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

WWE Wipo information: entry into national phase

Ref document number: 2128212

Country of ref document: CA

Ref document number: 1993903428

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1993903428

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1993903428

Country of ref document: EP